A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

This is a global extension study to provide continued access to niraparib and further characterize the long-term safety of niraparib treatment in participants who are currently receiving treatment with niraparib within GlaxoSmithKline/TESARO-sponsored studies (NCT01847274, NCT02354586, NCT01905592, NCT03308942, NCT02657889) that has fulfilled the requirements for the primary objective.

Trial Details

NCT ID

NCT04641247

Phase

PHASE2

Sponsor

GlaxoSmithKline

Status

RECRUITING

Cancer Type

Breast Cancer

Interventions

Niraparib

Locations (sample)

Tucson, Arizona, United States|32.22174,-110.92648
Encinitas, California, United States|33.03699,-117.29198
Los Angeles, California, United States|34.05223,-118.24368
Whittier, California, United States|33.97918,-118.03284
Jacksonville, Florida, United States|30.33218,-81.65565

Key Eligibility Criteria

Participant is able to understand the study procedures and agrees to participate in the study by providing written informed consent.
Participant is willing and able to comply with scheduled visits, treatment plans, and any other study procedures.
Participant is currently receiving treatment with niraparib (as monotherapy or in combination) in a GlaxoSmithKline/TESARO-sponsored study that has…
Participant is currently benefiting from treatment with niraparib as assessed by the Investigator according to the parent study protocol requirements.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →